AGP Picks
View all

Chronic liver disease therapeutics market seen reaching $25.99 billion by 2030

3 hours ago
Chronic liver disease therapeutics market seen reaching $25.99 billion by 2030
By AI, Created 16:45 UTC, Nov 18, 2026, AGP -

The global market for chronic liver disease therapeutics is projected to grow from $15.88 billion in 2025 to $25.99 billion by 2030, fueled by rising alcohol use, broader screening and more advanced treatment options. North America held the largest share in 2025, while Asia-Pacific is expected to be the fastest-growing region.

Why it matters: - Chronic liver disease treatments are gaining importance as alcohol use, liver disease prevalence and diagnosis rates continue to rise. - The market’s projected growth signals more demand for drugs, monitoring tools and specialty liver care across hospitals and clinics. - Investment is shifting toward therapies for NASH, fibrosis and precision liver medicine.

What happened: - The Business Research Company published its Chronic Liver Diseases Therapeutics Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on November 18, 2026. - The report estimates the market will increase from $15.88 billion in 2025 to $17.56 billion in 2026. - The market is projected to reach $25.99 billion by 2030. - The report puts the market’s forecast CAGR at 10.3% through 2030.

The details: - Historic growth has been supported by better diagnosis of chronic liver ailments, wider use of antiviral drugs, better management of autoimmune liver diseases, expanded access to hospital-based liver treatments and more specialized hepatology services. - Future growth is expected to come from investment in NASH and fibrosis therapies, stronger demand for precision liver medicine, advances in biologic and targeted drug development, earlier intervention strategies and more clinical trial activity. - Expected trends include targeted liver therapies, disease-specific treatment approaches, broader combination drug regimens, more non-invasive monitoring tools and efforts to slow disease progression. - Chronic liver disease therapeutics include medications, lifestyle modifications and specialized procedures used to slow disease progression, ease symptoms and improve liver function. - Rising alcohol consumption is a major market driver. - First Citizens Bank reported a 1.2% rise in direct-to-consumer wine case sales in 2023 compared with 2022. - Kirin Holdings said beer consumption reached about 192.1 million kiloliters in 2022, up 2.9% from 2021. - Wider use of antiviral therapies, improved screening and more specialty liver care are also supporting market growth. - North America held the largest market share in 2025. - Asia-Pacific is expected to grow fastest in the coming years. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

Between the lines: - The market outlook reflects a shift from broad liver-disease care toward more targeted treatment strategies. - Non-invasive monitoring and combination regimens suggest a push to manage disease earlier and more continuously. - The regional split points to mature demand in North America and faster adoption potential in Asia-Pacific.

What's next: - The report expects continued product development in targeted and biologic therapies. - Clinical trial activity around liver disease should remain elevated as companies pursue new treatments. - Healthcare systems are likely to expand screening, diagnosis and specialty liver services as demand rises. - The full report is available here. - A free sample is available here.

The bottom line: - Chronic liver disease therapeutics is moving into a faster-growth phase, with demand driven by rising alcohol use, broader care access and more advanced treatment approaches.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

The Europe Daily Report

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The Europe Daily Report

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.